News & Events

Other Events. Discontinuation of Legacy Biotechnology Business On May 21, 2026, the Board approved the discontinuation and structured wind-down of the Company’s legacy biotechnology business segment. Prior to reaching this determination, the Company’s management evaluated strategic alternatives for the segment, including a potential sale of the business. Based on this evaluation, the Board concluded that an orderly wind-down is in the best interests of the Company and its stockholders. The Co…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Co-Chief Executive Officer and Director On May 21, 2026, Kevin Richardson II notified AIxCrypto Holdings, Inc.’s (the “Company”) board of directors (the “Board”) of his resignation from the positions of Co-Chief Executive Officer and director of the Company, effective immediately. Mr. Richardson’s departure is not the result of any d…

Entry into a Material Definitive Agreement. On May 12, 2026, the AIxCrypto Holdings, Inc., a Delaware corporation (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with CABG ACQUISITION CORP. (“Buyer”), pursuant to which the Company agreed to sell, assign, and transfer to the Buyer, all of the Company’s right, title, and interest in the Note Package (as such term is defined in the Note Purchase Agreement), which includes (a) that certain Amended and Resta…

Results of Operations and Financial Condition On May 11, 2026, the Company issued a press release announcing its financial and operational results for the three months ended March 31, 2026, and an investor webcast that occurred on May 11, 2026 to discuss such results and update shareholders on general corporate developments. The press release and the investor presentation are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K (this “Form 8-K”) and are incorpo…

Entry into a Material Definitive Agreement Amendments of Entrusted Investment Agreement As previously disclosed by AIxCrypto Holdings, Inc., a Delaware corporation (the “Company”), in its Current Report on Form 8-K filed with the SEC on February 2, 2026 (the “February 8-K”), the Company entered into an entrusted investment agreement (the “Entrusted Investment Agreement”) with GOLD KING ARTHUR HOLDING LIMITED (“GKA”) and Song Wang (“Song”), under which the Company entrusted to GKA to manage an…

Results of Operations and Financial Condition On March 24, 2026, the Company issued a press release announcing its financial and operational results for the fiscal year ended December 31, 2025, and an investor webcast that occurred on March 24, 2026 to discuss such results and update shareholders on general corporate developments. The press release and the investor presentation are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K (this “Form 8-K”) and are i…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Entry into Employment Agreement with Co-Chief Executive Officer As previously disclosed by the Company in its Current Report on Form 8-K, filed with the SEC on October 6, 2025, effective as of October 2, 2025, the Company appointed Jiawei Wang (“Mr. Wang”) as the Co-Chief Executive Officer of the Company. In connection with his appointment, the Com…

Entry into a Material Definitive Agreement Entry into Advisor Agreement On February 10, 2026, AIxCrypto Holdings, Inc. (the “Company”) entered into an advisor agreement (the “Advisor Agreement”), effective as of October 2, 2025, with Yueting (YT) Jia (“Advisor”). Pursuant to the Advisor Agreement, the Company has engaged Advisor to provide a range of consulting services to support the Company’s strategic goals, including to serve as Chief Advisor for the Company (the “Services”). The services…

Other Events On January 27, 2026, the Company entered into a non-binding letter of intent (“LOI”) with Aster Foundation, a Cayman Islands foundation company (“Aster”), under which the Company and Aster would use commercially reasonable efforts to collaborate on general business opportunities and to share such capabilities with proposed areas and scope of collaboration as agreed between the parties, which includes collaboration on efforts relating to the Sei blockchain infrastructure. Addition…

Entry into a Material Definitive Agreement Entry into a Consulting Agreement On January 28, 2026, AIxCrypto Holdings, Inc. (the “Company”) entered into a consulting services agreement (the “Consulting Agreement”), effective as of November 1, 2025, with FF Global Partners LLC (“Consultant”). Pursuant to the Consulting Agreement, the Company has engaged Consultant to provide a range of consulting services to support the Company’s strategic goals. The services to be provided by Consultant includ…

Changes in Registrant’s Certifying Accountant. On December 12, 2025, the Audit Committee of the Board of Directors of AIxCrypto Holdings, Inc., a corporation incorporated under the laws of the State of Delaware (the “Company”) terminated Macias Gini & O’Connell LLP (“MGO”) as the independent registered public accounting firm of the Company. During the Company’s two most recent fiscal years and the subsequent interim period through December 12, 2025, there were no disagreements with MGO on any…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Non-Compliance with Nasdaq Listing Rule 5635(b) On November 18, 2025, the Company received a letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to comply with Nasdaq’s shareholder approval requirements set forth in Nasdaq Listing Rule 5635(b) (the “Rule”), which requires shareholder appro…

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Director Appointments On November 17, 2025, the Nominating and Governance Committee (the “Committee”) of Qualigen Therapeutics, Inc. (the “Company”) appointed Koti Meka as an Executive Director of the Company. Mr. Meka, age 55, serves as the Chief Financial Officer of both the Company and Faraday Future Intelligent Electric Inc., where he has managed finance operations, led financial planni…

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Officer Appointments Effective October 2, 2025, the Company appointed Jiawei Wang as the Co-Chief Executive Officer of the Company. Mr. Wang, age 34, currently serves as President of the Faraday Future Intelligent Electric Inc. (“FF”), and was the FF’s Vice President of Global Capital Markets from May 2018 to April 2022. Prior to that, he was Global Head of Capital Markets at FF from Januar…

Changes in Registrant’s Certifying Accountant. Resignation of Independent Registered Public Accounting Firm On October 1, 2025, WithumSmith+Brown, PC (“Withum”) notified the Audit Committee of the Board of Directors (the “Audit Committee”) of Qualigen Therapeutics, Inc. (the “Company”) that it had resigned as the Company’s independent registered public accounting firm, effective immediately. The Audit Committee accepted Withum’s resignation. Withum advised the Company in writing (the “Notice”…

Entry into a Material Definitive Agreement. Private Placement Offering On September 19, 2025, Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with certain investors (the “Suscribers”), including Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI)(the “Lead Investor”) pursuant to which the investors agreed to purchase $41,000,000 in cash (the “Offering”) of the Company’s common stock, par value $0.001…

Unregistered Sales of Equity Securities. The information under

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On September 4, 2025, Qualigen Therapeutics, Inc. (the “Company”) received a written decision (the “Decision Letter”) from the Nasdaq Hearings Panel (the “Panel”) in response to the Company’s August 19, 2025 update and request for a compliance determination with respect to the Panel’s July 24, 2025 decision, as amended. As previously disclosed, on July 24, 2025, the Panel granted the Company an…

Entry into a Material Definitive Agreement. On August 21, 2025, Qualigen Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Secured Demand Promissory Note (the “Amended Note”) with Marizyme, Inc. (“Marizyme”), which amends and restates in its entirety the terms of the prior secured promissory note originally issued by Marizyme to the Company on July 12, 2024, in the original principal amount of $1,250,000 (as previously amended, the “Prior Note”). The Amended Note has a p…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Other Information. As previously reported on a Current Report on Form 8-K filed with the Securities and Exchange Commission on July 28, 2025, the Company consummated on July 28, 2025 a private placement of 4,500 shares of its Series A-3 Preferred Stock at a purchase price of $1,000 per share, for aggregate gross proceeds of approximately $4.5 million, before deducting placement agent fees and offering expenses, resulting in net proceeds of $4,257,937.50. A pro forma balance sheet as of June 3…

of this Current Report on Form 8-K, the Company filed a Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A-3 Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware. The Certificate of Designation designates 10,000 shares of Series A-3 Preferred Stock. Each share of Series A-3 Preferred Stock has a stated value of $1,000 (the “Stated Value”) and is convertible, at the option of the holder, a…

Unregistered Sales of Equity Securities. The Series A-3 Preferred Stock discussed in

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On July 23, 2025, Qualigen Therapeutics, Inc. (the “Company”) received a written notice from the Nasdaq Listing Qualifications Department stating that, as reflected in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2025, the Company no longer satisfies the minimum $2.5 million stockholders’ equity requirement for continued listing under Nasdaq Listing Rule 5550(b)(1)…

Other Events. In connection with the private placement of Series A-3 Preferred Stock described in